Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07201194 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Holistic Acupuncture for Patients With Chemotherapy Induced Nausea

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Apr 2026 to Apr 2027
    • Study completion date: Dec 31, 2026 to Dec 31, 2027
    v3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Oct 2025 to Nov 17, 2025
    • Site details revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Vejle Hospital
29 trials monitored
See 2 trials at risk
Breast Cancer
5,418 trials monitored
See 296 trials at risk
Lung Cancer
4,790 trials monitored
See 263 trials at risk
Colorectal Cancer
3,394 trials monitored
See 159 trials at risk
and 2 more diseases
The study explores whether acupuncture as a supplement to conventional antiemetic medicine is superior in reducing the level of chemotherapy induced nausea compared to conventional anitemetic medicine alone. A total of 90 patients experiencing chemotherapy induced nausea will be allocated 1:1 to either acupuncture and antiemetic medicine or antiemetic medicine alone. The level of nausea and other cancer related symptoms will be assessed at baseline and 8 and 22 days after enrollment
Trial Details
NCT Number NCT07201194
Lead Sponsor Vejle Hospital
Conditions
(from sponsor)		 Breast Cancer, Prostate Cancer, Lung Cancer, Gynaecologic Cancer, Colorectal Cancer, Pancreatic Cancer Metastatic
Related terms Breast Neoplasms, Colorectal Neoplasms, Lung Neoplasms, Prostatic Neoplasms
Enrollment 90 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov